TriSalus Life Sciences (NASDAQ:TLSI) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) from a hold rating to a sell rating in a research report report published on Saturday.

TLSI has been the subject of several other research reports. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Canaccord Genuity Group lifted their price target on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $11.00.

TriSalus Life Sciences Trading Down 10.1%

TLSI opened at $5.53 on Friday. The company has a fifty day moving average price of $6.23 and a two-hundred day moving average price of $5.24. TriSalus Life Sciences has a 1-year low of $3.42 and a 1-year high of $7.95. The company has a market cap of $276.28 million, a P/E ratio of -2.74 and a beta of 0.43.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The firm had revenue of $11.57 million during the quarter, compared to the consensus estimate of $11.76 million. On average, research analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Hedge Funds Weigh In On TriSalus Life Sciences

Several large investors have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey purchased a new position in TriSalus Life Sciences during the 2nd quarter worth $29,000. JPMorgan Chase & Co. boosted its holdings in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in TriSalus Life Sciences in the 2nd quarter worth about $47,000. Sequoia Financial Advisors LLC bought a new stake in TriSalus Life Sciences in the 3rd quarter worth about $90,000. Finally, New York State Common Retirement Fund purchased a new stake in TriSalus Life Sciences in the 2nd quarter valued at about $108,000. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.